Video

Dr. Michael Williams on Treating Subtypes of MCL

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses personalized medicine in mantle cell lymphoma (MCL).

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses personalized medicine in mantle cell lymphoma (MCL).

An important area of interest in MCL is the tailoring of treatment to individual subtypes, says Williams. MCL is not one disease, but a spectrum of disease. About 20% of patients have very indolent disease that can be observed without treatment, while others have blastoid variant MCL, a very aggressive subtype of the disease.

These subtypes need to be taken into account as therapy is crafted for individual patients, and there will not be a one-size fits all approach, says Williams.

Related Videos
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Al Malki
Ian Krop MD, PhD
Timothy S. Fenske, MD, MS
Ignacio Garrido-Laguna, MD, PhD, MBA
Marwan G. Fakih, MD
Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
Werutsky